Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US

Kong, Amanda M.; Pavilack, Melissa; Huo, Hairong; Shenolikar, Rahul; Moynihan, Meghan; Marchlewicz, Elizabeth H.; Chebili-Larson, Christina; Min, Stella; Subramaniam, Deepa

doi:10.1080/13696998.2021.1885418

Cited by 2 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, on the basis of 23 observational studies, a range of 12.3–81.5% patients were reported to have asymptomatic brain metastases at baseline (Table 3 ). Among the three observational studies that reported symptoms, headache, nausea, and mental changes were the most frequently reported [ 30 , 46 , 64 ]. Patients who were asymptomatic were more likely to have been treated with EGFR TKIs only or EGFR TKIs plus SRS compared with patients who were treated with WBRT alone or in combination with another type of therapy.…”

Section: Resultsmentioning

confidence: 99%

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review

Khasraw,

Yalamanchili,

Santhanagopal

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis. During the disease course, 25–50% of patients will develop BrMs. Despite available treatments, survival rates for patients with NSCLC and BrMs remain low, and their overall prognosis is poor. Even with newer agents for NSCLC, options for treating BrMs can be limited by their ineffective transport across the blood–brain barrier (BBB) and the unique brain tumor microenvironment. The presence of actionable genomic alterations (AGAs) is a key determinant of optimal treatment selection, which aims to maximize responses and minimize toxicities. The objective of this systematic literature review (SLR) was to understand the current landscape of the clinical management of patients with NSCLC and BrMs, particularly those with AGAs. Method A Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)-compliant SLR was conducted to identify studies in patients with BrMs in NSCLC. Searches used the EMBASE and MEDLINE ® databases, and articles published between January 1, 2017 and September 26, 2022 were reviewed. Results Overall, 179 studies were included in the SLR. This subset review focused on 80 studies that included patients with NSCLC, BrMs, and AGAs (19 randomized controlled trials [RCTs], two single-arm studies, and 59 observational studies). Sixty-four of the 80 studies reported on epidermal growth factor receptor ( EGFR ) mutations, 14 on anaplastic lymphoma kinase ( ALK ) alterations, and two on both alterations. Ninety-five percent of studies evaluated targeted therapy. All RCTs allowed patients with previously treated, asymptomatic, or neurologically stable BrMs; the percentage of asymptomatic BrMs varied across observational studies. Conclusions Although targeted therapies demonstrate systemic benefits for patients with NSCLC, BrMs, and AGAs, there remains a continued need for effective therapies to treat and prevent BrMs in this population. Increased BBB permeability of emerging therapies may improve outcomes for this population. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-024-02799-9.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review

Khasraw,

Yalamanchili,

Santhanagopal

et al. 2024

Adv Ther

View full text Add to dashboard Cite

show abstract

Hospital frailty risk score predicts high-value care outcomes following brain metastasis resection

Kazemi,

Ahmed,

Roy

et al. 2024

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US

Abstract: View related articles View Crossmark data Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US Economic burden of brain metastases in NSCLC

Cited by 2 publications

References 34 publications

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review

Hospital frailty risk score predicts high-value care outcomes following brain metastasis resection

Contact Info

Product

Resources

About